Dr. Jordan goes to DC: Father of tamoxifen joins Lombardi

Publication
Article
Oncology NEWS Today BlogOncology NEWS Today Blog Vol 18 No 5
Volume 18
Issue 5

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

Dr. Jordan will take up his post at the Washington, DC-based institutions in July. He will also occupy an endowed chair. Dr. Jordan currently serves as vice president and scientific director for the medical sciences at Fox Chase Cancer Center in Philadelphia, where he holds the Alfred G. Knudson Jr., MD, PhD, Chair in Cancer Research. Dr. Jordan is also an adjunct professor of cancer biology at the University of Pennsylvania and a visiting professor of molecular medicine at the University of Leeds in England.

To learn more about Dr. Jordan’s life and career in “Father of tamoxifen a Brit to the core,” May 2008, visit www.cancernetwork.com

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.